ES2111068T3 - Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma. - Google Patents

Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma.

Info

Publication number
ES2111068T3
ES2111068T3 ES92911883T ES92911883T ES2111068T3 ES 2111068 T3 ES2111068 T3 ES 2111068T3 ES 92911883 T ES92911883 T ES 92911883T ES 92911883 T ES92911883 T ES 92911883T ES 2111068 T3 ES2111068 T3 ES 2111068T3
Authority
ES
Spain
Prior art keywords
protein
tap
trichosanthes
same
therapeutic uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911883T
Other languages
English (en)
Inventor
Sylvia Lee-Huang
Philip L Huang
Hao-Chia Chen
Hsiang-Fu Kung
Peter Huang
Henry I Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Abraxis Bioscience LLC
US Department of Health and Human Services
Original Assignee
American Bioscience Inc
New York University NYU
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Bioscience Inc, New York University NYU, US Department of Health and Human Services filed Critical American Bioscience Inc
Application granted granted Critical
Publication of ES2111068T3 publication Critical patent/ES2111068T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UNA NUEVA PROTEINA, DENOMINADA TAP 29, OBTENIBLE A PARTIR DE LA PLANTA TRICHOSANTHES KIRILOWII O PRODUCIDA POR MEDIOS DE RECOMBINACION SE USA PARA TRATAR INFECCIONES DE VIH O TUMORES. EN TRATAMIENTO DE INFECCIONES DE VIH, LA PROTEINA SE ADMINISTRA SOLA O EN CONJUNCION CON TERAPIAS CONVENCIONALES PARA SIDA. TAMBIEN SE PROVEEN PROCESOS PARA PURIFICAR LA PROTEINA, SECUENCIAS DE DNA CODIFICANDO LA PROTEINA, ANFITRIONES QUE EXPRESAN LA PROTEINA, METODOS DE RECOMBINACION DE DNA PARA EXPRESAR LA PROTEINA, Y ANTICUERPOS ESPECIFICOS PARA LA PROTEINA.
ES92911883T 1991-04-15 1992-04-15 Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma. Expired - Lifetime ES2111068T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68512691A 1991-04-15 1991-04-15

Publications (1)

Publication Number Publication Date
ES2111068T3 true ES2111068T3 (es) 1998-03-01

Family

ID=24750879

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911883T Expired - Lifetime ES2111068T3 (es) 1991-04-15 1992-04-15 Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma.

Country Status (11)

Country Link
US (1) US5532214A (es)
EP (1) EP0580782B1 (es)
JP (1) JPH06506949A (es)
AT (1) ATE159032T1 (es)
AU (1) AU672749B2 (es)
CA (1) CA2108467A1 (es)
DE (1) DE69222636T2 (es)
DK (1) DK0580782T3 (es)
ES (1) ES2111068T3 (es)
GR (1) GR3025841T3 (es)
WO (1) WO1992018148A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5681815A (en) * 1993-06-28 1997-10-28 Sophie Chen Antiviral and antitumor agents
EP0948347A4 (en) * 1997-07-16 2000-08-30 Sophie Chen ANTI-VIRALS AND ANTI-TUMOR ACTIVE SUBSTANCES
CN1152051C (zh) 2000-08-02 2004-06-02 北京翔天牧生物科技有限公司 一种天花粉蛋白突变体及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601680B1 (fr) * 1986-07-15 1990-06-29 Sanofi Sa Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant
US5149528A (en) * 1987-04-10 1992-09-22 Zymogenetics, Inc. Cytotoxic protein from Trichosanthes kirilowii
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
US4869903A (en) * 1987-05-29 1989-09-26 Genelabs Incorporated Method of selectively inhibiting HIV
US4795739A (en) * 1987-05-29 1989-01-03 Gene Labs, Inc. Method of inhibiting HIV
US5166056A (en) * 1989-04-04 1992-11-24 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5077390A (en) * 1989-04-04 1991-12-31 Genelabs, Incorporated Purified trichosanthin and method of preparation
JPH04504208A (ja) * 1989-04-04 1992-07-30 ジエネラブス・テクノロジーズ・インコーポレイテツド 組換えトリコサンチンおよびコード配列

Also Published As

Publication number Publication date
DK0580782T3 (da) 1998-05-04
EP0580782B1 (en) 1997-10-08
DE69222636T2 (de) 1998-02-05
EP0580782A4 (en) 1995-04-26
ATE159032T1 (de) 1997-10-15
GR3025841T3 (en) 1998-04-30
JPH06506949A (ja) 1994-08-04
CA2108467A1 (en) 1992-10-16
AU672749B2 (en) 1996-10-17
EP0580782A1 (en) 1994-02-02
AU1973792A (en) 1992-11-17
US5532214A (en) 1996-07-02
WO1992018148A1 (en) 1992-10-29
DE69222636D1 (de) 1997-11-13

Similar Documents

Publication Publication Date Title
ES2003863A4 (es) Procedimiento para producir una preparacion de liberacion controlada de metoprolol y uso de dicha preparacion.
ATE179425T1 (de) Verfahren zur abreicherung oder entfernung von endotoxinen
SE7707992L (sv) Forfarande for framstellning av en blodkoagulationsbefremjande preparation av humanblodplasma
MY104992A (en) Composition inducing a binding.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
ES2054353T3 (es) Expresion de las alipoproteinas humanas ai-milano en levadura.
DK548986A (da) Praeparat til behandling af acne vulgaris og fremgangsmaade til dets fremstilling og anvendelse
DE69233143D1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
ES2023848B3 (es) Agentes para revitalizar, estimular y fortalecer el crecimiento del cabello.
ES2111068T3 (es) Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma.
DE69131253D1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE3584926D1 (de) Behandlung von oedemen mit hohem proteingehalt durch direktes aufbringen von benzopyronen.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
GB1018528A (en) New physiologically active protein fractions from mistletoe and process for their preparation
DE3578135D1 (de) Behandlung eines ultrafiltrats durch elektrodialyse.
MX9206135A (es) Metodos
MX9201288A (es) Metodo de tratamiento.
RU97106986A (ru) Средство и способ лечения ишемического инсульта
JPS522433A (en) Single bath color element silver branching liquid
ZA856160B (en) Antiseptic product and a method of manufacture of the said product
SI0817786T1 (en) Substituted tetronic acids useful for treating hiv and other retroviruses
DK0470144T3 (da) D-Asparaginsyre-beta-hydroxamat til behandling af virale infektioner og tumorer
EP0321094A3 (en) Treatment of factor viii inhibitors
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
JPS5369880A (en) Preparation of lactic acid

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 580782

Country of ref document: ES